---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036995"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:41:11.870999+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q2 revenue up 6% to $2.2M; gross margin expands to 67.2%

## Summary
- Revenue $2.2M (+6% YoY); Critical Care revenue up 28%, Heart Failure consumables utilization up 35%.
- Gross margin 67.2% vs 55.3% prior year; total operating expenses down 38% to $3.8M.
- Net loss $7.7M vs $4.8M; basic EPS loss $18.85 vs $127.65 (improved due to share count changes).
- Cash and equivalents $1.0M; no debt; closed registered direct offering for $2.0M gross proceeds on July 25.
- Expanded Aquadex to pediatric patients in Florida hospital network; signed purchase agreement with 50-hospital Texas network.

## SEC filing metadata
- accession: 0001140361-24-036995
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036124036995/0001140361-24-036995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036124036995/ef20033985_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036995
- JSON: https://secwatch.observer/filing/0001140361-24-036995.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036995.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.